Research ExplorerPublicationsAssociation Between Obesity and Circulating Tumor Cells in E...

Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer Patients

Standard

Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer Patients. / Tzschaschel, Marie; Friedl, Thomas W P; Schochter, Fabienne; Schütze, Sabine; Polasik, Arkadius; Fehm, Tanja; Pantel, Klaus; Schindlbeck, Christian; Schneeweiss, Andreas; Schreier, Jörg; Tesch, Hans; Lorenz, Ralf; Aivazova-Fuchs, Viktoria; Häberle, Lothar; Fasching, Peter; Janni, Wolfgang; Rack, Brigitte Kathrin; Fink, Visnja.

In: CLIN BREAST CANCER, Vol. 23, No. 6, 08.2023, p. e345-e353.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Tzschaschel, M, Friedl, TWP, Schochter, F, Schütze, S, Polasik, A, Fehm, T, Pantel, K, Schindlbeck, C, Schneeweiss, A, Schreier, J, Tesch, H, Lorenz, R, Aivazova-Fuchs, V, Häberle, L, Fasching, P, Janni, W, Rack, BK & Fink, V 2023, 'Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer Patients', CLIN BREAST CANCER, vol. 23, no. 6, pp. e345-e353. https://doi.org/10.1016/j.clbc.2023.05.011

APA

Tzschaschel, M., Friedl, T. W. P., Schochter, F., Schütze, S., Polasik, A., Fehm, T., Pantel, K., Schindlbeck, C., Schneeweiss, A., Schreier, J., Tesch, H., Lorenz, R., Aivazova-Fuchs, V., Häberle, L., Fasching, P., Janni, W., Rack, B. K., & Fink, V. (2023). Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer Patients. CLIN BREAST CANCER, 23(6), e345-e353. https://doi.org/10.1016/j.clbc.2023.05.011

Vancouver

Tzschaschel M, Friedl TWP, Schochter F, Schütze S, Polasik A, Fehm T et al. Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer Patients. CLIN BREAST CANCER. 2023 Aug;23(6):e345-e353. https://doi.org/10.1016/j.clbc.2023.05.011

Bibtex

@article{39d083108b564f429a50cdb30523cfd0,
title = "Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer Patients",
abstract = "BACKGROUND: Obesity and the presence of circulating tumor cells (CTCs) before and/or after chemotherapy are associated with poor outcome in breast cancer (BC) patients. The activation of oncogenic pathways in fatty tissue leads to cell proliferation, suggesting a possible link between obesity and CTCs.MATERIALS AND METHODS: In the phase III SUCCESS A trial, 3754 patients with early BC were randomized to 3 cycles of fluorouracil, epirubicin and cyclophosphamide followed by 3 cycles of docetaxel with or without gemcitabine. Data of 1088 patients with CTC assessments (CellSearch-System; Menarini Silicon Biosystems, Italy) and body mass index (BMI) measurements both before and after chemotherapy were available. Patients were classified according to the WHO's international definitions as underweight, normal weight, overweight, or obese, and according to their weight-change during chemotherapy into a weight-loss group (> 5% decrease), stable-weight group (≤ 5% weight-change) or weight-gain group (>5% increase). Associations between CTC positivity and, BMI or weight-change group were analyzed using frequency-table methods.RESULTS: At study entry, 47.4% patients were underweight or normal weight, 33.6% were overweight and 18.9% were obese. Before and after chemotherapy, CTCs were detected in 20.1% and 22.6% of patients, respectively. There was no association between CTC positivity and BMI before (P = 0.104) or after (P = 0.051) chemotherapy. Furthermore, there was no association between weight-change group and CTC status before/after chemotherapy (P = 0.332).CONCLUSIONS: According to our analysis, the risk factors obesity and prevalence of CTCs are not associated and may represent independent prognostic factors.",
keywords = "Humans, Female, Breast Neoplasms/drug therapy, Neoplastic Cells, Circulating/pathology, Overweight, Thinness, Prognosis, Obesity/complications, Biomarkers, Tumor/metabolism",
author = "Marie Tzschaschel and Friedl, {Thomas W P} and Fabienne Schochter and Sabine Sch{\"u}tze and Arkadius Polasik and Tanja Fehm and Klaus Pantel and Christian Schindlbeck and Andreas Schneeweiss and J{\"o}rg Schreier and Hans Tesch and Ralf Lorenz and Viktoria Aivazova-Fuchs and Lothar H{\"a}berle and Peter Fasching and Wolfgang Janni and Rack, {Brigitte Kathrin} and Visnja Fink",
note = "Copyright {\textcopyright} 2023. Published by Elsevier Inc.",
year = "2023",
month = aug,
doi = "10.1016/j.clbc.2023.05.011",
language = "English",
volume = "23",
pages = "e345--e353",
journal = "CLIN BREAST CANCER",
issn = "1526-8209",
publisher = "Elsevier",
number = "6",

}

RIS

TY - JOUR

T1 - Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer Patients

AU - Tzschaschel, Marie

AU - Friedl, Thomas W P

AU - Schochter, Fabienne

AU - Schütze, Sabine

AU - Polasik, Arkadius

AU - Fehm, Tanja

AU - Pantel, Klaus

AU - Schindlbeck, Christian

AU - Schneeweiss, Andreas

AU - Schreier, Jörg

AU - Tesch, Hans

AU - Lorenz, Ralf

AU - Aivazova-Fuchs, Viktoria

AU - Häberle, Lothar

AU - Fasching, Peter

AU - Janni, Wolfgang

AU - Rack, Brigitte Kathrin

AU - Fink, Visnja

N1 - Copyright © 2023. Published by Elsevier Inc.

PY - 2023/8

Y1 - 2023/8

N2 - BACKGROUND: Obesity and the presence of circulating tumor cells (CTCs) before and/or after chemotherapy are associated with poor outcome in breast cancer (BC) patients. The activation of oncogenic pathways in fatty tissue leads to cell proliferation, suggesting a possible link between obesity and CTCs.MATERIALS AND METHODS: In the phase III SUCCESS A trial, 3754 patients with early BC were randomized to 3 cycles of fluorouracil, epirubicin and cyclophosphamide followed by 3 cycles of docetaxel with or without gemcitabine. Data of 1088 patients with CTC assessments (CellSearch-System; Menarini Silicon Biosystems, Italy) and body mass index (BMI) measurements both before and after chemotherapy were available. Patients were classified according to the WHO's international definitions as underweight, normal weight, overweight, or obese, and according to their weight-change during chemotherapy into a weight-loss group (> 5% decrease), stable-weight group (≤ 5% weight-change) or weight-gain group (>5% increase). Associations between CTC positivity and, BMI or weight-change group were analyzed using frequency-table methods.RESULTS: At study entry, 47.4% patients were underweight or normal weight, 33.6% were overweight and 18.9% were obese. Before and after chemotherapy, CTCs were detected in 20.1% and 22.6% of patients, respectively. There was no association between CTC positivity and BMI before (P = 0.104) or after (P = 0.051) chemotherapy. Furthermore, there was no association between weight-change group and CTC status before/after chemotherapy (P = 0.332).CONCLUSIONS: According to our analysis, the risk factors obesity and prevalence of CTCs are not associated and may represent independent prognostic factors.

AB - BACKGROUND: Obesity and the presence of circulating tumor cells (CTCs) before and/or after chemotherapy are associated with poor outcome in breast cancer (BC) patients. The activation of oncogenic pathways in fatty tissue leads to cell proliferation, suggesting a possible link between obesity and CTCs.MATERIALS AND METHODS: In the phase III SUCCESS A trial, 3754 patients with early BC were randomized to 3 cycles of fluorouracil, epirubicin and cyclophosphamide followed by 3 cycles of docetaxel with or without gemcitabine. Data of 1088 patients with CTC assessments (CellSearch-System; Menarini Silicon Biosystems, Italy) and body mass index (BMI) measurements both before and after chemotherapy were available. Patients were classified according to the WHO's international definitions as underweight, normal weight, overweight, or obese, and according to their weight-change during chemotherapy into a weight-loss group (> 5% decrease), stable-weight group (≤ 5% weight-change) or weight-gain group (>5% increase). Associations between CTC positivity and, BMI or weight-change group were analyzed using frequency-table methods.RESULTS: At study entry, 47.4% patients were underweight or normal weight, 33.6% were overweight and 18.9% were obese. Before and after chemotherapy, CTCs were detected in 20.1% and 22.6% of patients, respectively. There was no association between CTC positivity and BMI before (P = 0.104) or after (P = 0.051) chemotherapy. Furthermore, there was no association between weight-change group and CTC status before/after chemotherapy (P = 0.332).CONCLUSIONS: According to our analysis, the risk factors obesity and prevalence of CTCs are not associated and may represent independent prognostic factors.

KW - Humans

KW - Female

KW - Breast Neoplasms/drug therapy

KW - Neoplastic Cells, Circulating/pathology

KW - Overweight

KW - Thinness

KW - Prognosis

KW - Obesity/complications

KW - Biomarkers, Tumor/metabolism

U2 - 10.1016/j.clbc.2023.05.011

DO - 10.1016/j.clbc.2023.05.011

M3 - SCORING: Journal article

C2 - 37336651

VL - 23

SP - e345-e353

JO - CLIN BREAST CANCER

JF - CLIN BREAST CANCER

SN - 1526-8209

IS - 6

ER -